<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486391</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-314</org_study_id>
    <secondary_id>CTR20201517</secondary_id>
    <nct_id>NCT04486391</nct_id>
  </id_info>
  <brief_title>Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of tislelizumab in&#xD;
      participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by&#xD;
      Progression-free Survival (PFS) as assessed by investigator&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">March 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response (CR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The proportion of participants who achieves a best overall response of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Time from the date of randomization to the time the response criteria are first met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Defined as the time from the date of randomization to the date of death due to any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tislelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab monotherapy for up to 45 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salvage chemotherapy for up to 45 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200 mg administered via intravenous (IV) infusion once every 3 weeks</description>
    <arm_group_label>Tislelizumab</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvage Chemotherapy</intervention_name>
    <description>Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)</description>
    <arm_group_label>Salvage chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria :&#xD;
&#xD;
          1. Histologically confirmed cHL.Must have relapsed or refractory ( cHL and&#xD;
&#xD;
               1. Has failed to achieve a response or progressed after autologous hematopoietic&#xD;
                  stem cell transplant (ASCT). or&#xD;
&#xD;
               2. Has received at least two prior lines of systemic chemotherapies for cHL and is&#xD;
                  not an ASCT candidate.&#xD;
&#xD;
          2. Must have measurable disease d3. Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status of 0 or 1.&#xD;
&#xD;
          3. Must have adequate organ functions.&#xD;
&#xD;
          4. Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy used to&#xD;
             control cancer including locoregional treatment must have been completed â‰¥ 4 weeks&#xD;
             before the first dose of study drug, and all treatment-related adverse events are&#xD;
             stable and have either returned to baseline or Grade 0/1&#xD;
&#xD;
        Key Exclusion Criteria :&#xD;
&#xD;
          1. Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma. Known central&#xD;
             nervous system (CNS) lymphoma.&#xD;
&#xD;
          2. Prior allogeneic hematopoietic stem cell transplant. ASCT or Chimeric Antigen Receptor&#xD;
             T-Cell Immunotherapy (CAR-T) within 100 days of first dose of study drug.&#xD;
&#xD;
          3. Prior therapies targeting PD-1 or PD-L1.&#xD;
&#xD;
          4. Prior malignancy within the past 3 years except for curatively treated basal or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the&#xD;
             cervix or breast.&#xD;
&#xD;
          5. Participant with active autoimmune disease or history of autoimmune disease with high&#xD;
             risk of recurrence.&#xD;
&#xD;
          6. Serious acute or chronic infection requiring systemic therapy.&#xD;
&#xD;
          7. Known human immunodeficiency virus (HIV), or serologic status reflecting active&#xD;
             hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital Affiliated to Fujian Medical University</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

